Daxor Will Showcase Blood Diagnostic Tools in Denver
The company will demonstrate its FDA-cleared diagnostic platform to nephrology leaders at ASN Kidney Week 2026.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Should medical companies prioritize precision diagnostic technology to improve outcomes for local kidney patients?
Daxor Corporation will exhibit its blood volume analysis technology at the 59th annual ASN Kidney Week in Denver from October 21-25, 2026. The platform measures red blood cell, plasma, and total blood volume to support precision medicine for renal disease.
Why it matters
The exhibition aims to engage global nephrology experts as Daxor pursues accelerated market expansion for its diagnostic tools. Precision diagnostics in kidney care remain a high-stakes focus given that more than 850 million people worldwide live with kidney disease.
Daxor plans to highlight its diagnostic platform, which supports a patient population of 850 million people living with kidney disease. The company manufactures its technology at a 20,000-square-foot facility and will present at the 59th annual ASN Kidney Week.
The players
Daxor Corporation
A Nasdaq-listed medical instrumentation company that designs and manufactures diagnostic platforms for blood volume analysis.
ASN
The American Society of Nephrology, which organizes professional meetings for kidney health specialists.
The details
Daxor will operate from Booth #390 at the Colorado Convention Center. Representatives plan to provide live demonstrations of the FDA-cleared hardware and guide attendees through technical reimbursement pathways for integrating the diagnostic platform into clinical workflows.
Timeline
October 21-25, 2026: Daxor exhibits at ASN Kidney Week 2026.
Market Landscape
The push for precision blood volume analysis sits within the broader evolution of FDA-cleared diagnostic technologies in specialized nephrology care. This move signals a strategic effort to scale clinical adoption among international leaders in the field.
Operators in the diagnostic space should monitor the reimbursement pathway information presented by Daxor at the conference for potential shifts in clinical billing standards. The focus on high-volume renal disease monitoring may indicate a shift in standard-of-care expectations for nephrology practices.
The takeaway
Daxor is leveraging the ASN Kidney Week event to scale its market presence through direct clinical engagement. Operators should track the evolving reimbursement strategies highlighted during the meeting to understand how new diagnostics might be integrated into their own patient care models.
Further reading
For more information on diagnostic trends, visit the Healthcare section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical companies prioritize precision diagnostic technology to improve outcomes for local kidney patients?
